Vocke K, Dauner K, Hahn A, Ulbrich A, Broecker J, Keller S, Frings S and Möhrlen F: Calmodulin-dependent activation and inactivation of anoctamin calcium-gated chloride channels. J Gen Physiol. 142:381–404. 2013. View Article : Google Scholar : PubMed/NCBI

Whitlock JM and Hartzell HC: Anoctamins/TMEM16 proteins: Chloride channels flirting with lipids and extracellular vesicles. Annu Rev Physiol. 79:119–143. 2017. View Article : Google Scholar :

Kunzelmann K, Ousingsawat J, Benedetto R, Cabrita I and Schreiber R: Contribution of Anoctamins to cell survival and cell death. Cancers. 11:3822019. View Article : Google Scholar : PubMed/NCBI

Scudieri P, Sondo E, Ferrera L and Galietta LJV: The anoctamin family: TMEM16A and TMEM16B as calcium-activated chloride channels. Exp Physiol. 97:177–183. 2011. View Article : Google Scholar : PubMed/NCBI

Kim H, Kim H, Lee J, Lee B, Kim HR, Jung J, Lee MO and Oh U: Anoctamin 9/TMEM16J is a cation channel activated by cAMP/PKA signal. Cell Calcium. 71:75–85. 2018. View Article : Google Scholar : PubMed/NCBI

Khelashvili G, Falzone ME, Cheng X, Lee B-C, Accardi A and Weinstein H: Dynamic modulation of the lipid translocation groove generates a conductive ion channel in Ca2+-bound nhTMEM16. Nat Commun. 10:49722019. View Article : Google Scholar :

Agostinelli E and Tammaro P: Polymodal control of TMEM16x channels and Scramblases. Int J Mol Sci. 23:15802022. View Article : Google Scholar : PubMed/NCBI

Baethge C, Goldbeck-Wood S and Mertens S: SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 4:52019. View Article : Google Scholar : PubMed/NCBI

Falzone ME, Malvezzi M, Lee BC and Accardi A: Known structures and unknown mechanisms of TMEM16 scramblases and channels. J Gen Physiol. 150:933–947. 2018. View Article : Google Scholar : PubMed/NCBI

Falzone ME, Rheinberger J, Lee BC, Peyear T, Sasset L, Raczkowski AM, Eng ET, Di Lorenzo A, Andersen OS, Nimigean CM and Accardi A: Structural basis of Ca2+-dependent activation and lipid transport by a TMEM16 scramblase. ELife. 8:e432292019. View Article : Google Scholar :

Cheng Y, Feng S, Puchades C, Ko J, Figueroa E, Chen Y, Wu H, Gu S, Han T, Li J, et al: Identification of a conserved drug binding pocket in TMEM16 proteins. Res Sq. View Article : Google Scholar

Pedemonte N and Galietta LJV: Structure and function of TMEM16 proteins (Anoctamins). Physiol Rev. 94:419–459. 2014. View Article : Google Scholar : PubMed/NCBI

Yu K, Duran C, Qu Z, Cui YY and Hartzell HC: Explaining calcium-dependent gating of Anoctamin-1 chloride channels requires a revised topology. Circ Res. 110:990–999. 2012. View Article : Google Scholar : PubMed/NCBI

Jung J, Nam JH, Park HW, Oh U, Yoon JH and Lee MG: Dynamic modulation of ANO1/TMEM16A HCO3⁻ permeability by Ca²⁺/calmodulin. Proc Natl Acad Sci USA. 110:360–365. 2012. View Article : Google Scholar

Tian Y, Kongsuphol P, Hug M, Ousingsawat J, Witzgall R, Schreiber R and Kunzelmann K: Calmodulin-dependent activation of the epithelial calcium-dependent chloride channel TMEM16A. FASEB J. 25:1058–1068. 2010. View Article : Google Scholar : PubMed/NCBI

Hahn A, Salomon JJ, Leitz D, Feigenbutz D, Korsch L, Lisewski I, Schrimpf K, Millar-Büchner P, Mall MA, Frings S and Möhrlen F: Expression and function of Anoctamin 1/TMEM16A calcium-activated chloride channels in airways of in vivo mouse models for cystic fibrosis research. Pflugers Arch. 470:1335–1348. 2018. View Article : Google Scholar : PubMed/NCBI

Falzone ME, Feng Z, Alvarenga OE, Pan Y, Lee B, Cheng X, Fortea E, Scheuring S and Accardi A: TMEM16 scramblases thin the membrane to enable lipid scrambling. Nat Commun. 13:26042022. View Article : Google Scholar : PubMed/NCBI

Jansen K and Steurer S: DOG1 expression is in common human tumors: A tissue microarray study on more than 15,000 tissue samples. Am J Clin Pathol. 156(Suppl): S108–S109. 2021. View Article : Google Scholar

Lam AK and Dutzler R: Calcium-dependent electrostatic control of anion access to the pore of the calcium-activated chloride channel TMEM16A. ELife. 7:e391222018. View Article : Google Scholar : PubMed/NCBI

Huang WC, Xiao S, Huang F, Harfe BD, Jan YN and Jan L: Calcium-Activated chloride channels (CaCCs) regulate action potential and synaptic response in hippocampal neurons. Neuron. 74:179–192. 2012. View Article : Google Scholar : PubMed/NCBI

Davis AJ, Forrest AS, Jepps TA, Valencik ML, Wiwchar M, Singer CA, Sones WR, Greenwood IA and Leblanc N: Expression profile and protein translation of TMEM16A in murine smooth muscle. Am J Physiol Cell Physiol. 299:C948–C959. 2010. View Article : Google Scholar : PubMed/NCBI

Thomas-Gatewood C, Neeb ZP, Bulley S, Adebiyi A, Bannister JP, Leo MD and Jaggar JH: TMEM16A channels generate Ca²⁺-activated Cl-currents in cerebral artery smooth muscle cells. Am J Physiol Circ Physiol. 301:H1819–H1827. 2011. View Article : Google Scholar

Li RS, Wang Y, Chen HS, Jiang FY, Tu Q, Li WJ and Yin RX: TMEM16A contributes to angiotensin II-induced cerebral vasoconstriction via the RhoA/ROCK signaling pathway. Mol Med Report. 13:3691–3699. 2016. View Article : Google Scholar

Lian H, Cheng Y and Wu X: TMEM16A exacerbates renal injury by activating P38/JNK signaling pathway to promote podocyte apoptosis in diabetic nephropathy mice. Biochem Biophys Res Commun. 487:201–208. 2017. View Article : Google Scholar : PubMed/NCBI

Dutta AK, Khimji AK, Liu S, Karamysheva Z, Fujita A, Kresge C, Rockey DC and Feranchak AP: PKCα regulates TMEM16A-mediated Cl-secretion in human biliary cells. Am J Physiol Liver Physiol. 310:G34–G42. 2016.

Arreola J, López-Romero AE, Pérez-Cornejo P and Rodríguez-Menchaca AA: Phosphatidylinositol 4,5-bisphosphate and cholesterol regulators of the calcium-activated chloride channels TMEM16A and TMEM16B. Adv Exp Med Biol. 1422:279–304. 2023. View Article : Google Scholar : PubMed/NCBI

Lee D, Lim H, Lee J, Ha GE, No KT and Cheong E: Intracellular loop in the brain isoforms of anoctamin 2 channels regulates calcium-dependent activation. Exp Neurobiol. 32:133–146. 2023. View Article : Google Scholar : PubMed/NCBI

Pietra G, Dibattista M, Menini A, Reisert J and Boccaccio A: The Ca²⁺-activated Cl-channel TMEM16B regulates action potential firing and axonal targeting in olfactory sensory neurons. J Gen Physiol. 148:293–311. 2016. View Article : Google Scholar : PubMed/NCBI

Ayoglu B, Mitsios N, Kockum I, Khademi M, Zandian A, Sjöberg R, Forsström B, Bredenberg J, Lima Bomfim I, Holmgren E, et al: Anoctamin 2 identified as an autoimmune target in multiple sclerosis. Proc Natl Acad Sci USA. 113:2188–2193. 2016. View Article : Google Scholar : PubMed/NCBI

Ha GE, Lee J, Kwak H, Song K, Kwon J, Jung SY, Hong J, Chang GE, Hwang EM, Shin HS, et al: The Ca²⁺-activated chloride channel anoctamin-2 mediates spike-frequency adaptation and regulates sensory transmission in thalamocortical neurons. Nat Commun. 7:137912016. View Article : Google Scholar

Zhang Y, Zhang Z, Xiao S, Tien J, Le S, Le T, Jan LY and Yang H: Inferior Olivary TMEM16B mediates cerebellar motor learning. Neuron. 95:1103–1111.e4. 2017. View Article : Google Scholar : PubMed/NCBI

Kim H, Kim E and Lee BC: Investigation of phosphatidylserine-transporting activity of human TMEM16C isoforms. Membranes (Basel). 12:10052022. View Article : Google Scholar : PubMed/NCBI

Wang TA, Chen C, Huang F, Feng S, Tien J, Braz JM, Basbaum AI, Jan YN and Jan LY: TMEM16C is involved in thermoregulation and protects rodent pups from febrile seizures. Proc Natl Acad Sci USA. 118:e20233421182021. View Article : Google Scholar : PubMed/NCBI

Huang F, Wang X, Ostertag EM, Nuwal T, Huang B, Jan YN, Basbaum AI and Jan LY: TMEM16C facilitates Na(+)-activated K+ currents in rat sensory neurons and regulates pain processing. Nat Neurosci. 16:1284–1290. 2013. View Article : Google Scholar : PubMed/NCBI

Carvalho V, Martins J, Correia F, Costa M, Massano J and Temudo T: Another twist in the tale: Intrafamilial phenotypic heterogeneity in ANO3-related dystonia. Mov Disord Clin Pract. 8:758–762. 2021. View Article : Google Scholar : PubMed/NCBI

Stamelou M, Charlesworth G, Cordivari C, Schneider SA, Kägi G, Sheerin UM, Rubio-Agusti I, Batla A, Houlden H, Wood NW and Bhatia KP: The phenotypic spectrum of DYT24 due to ANO3 mutations. Mov Disord. 29:928–934. 2014. View Article : Google Scholar : PubMed/NCBI

Esposito M, Trinchillo A, Piceci-Sparascio F, D'Asdia MC, Consoli F and De Luca A: A novel ANO3 variant in two siblings with different phenotypes. Parkinsonism Relat Disord. 111:1054132023. View Article : Google Scholar : PubMed/NCBI

Reichhart N, Milenkovic VM, Wetzel CH and Strauß O: Prediction of functional consequences of missense mutations in ANO4 Gene. Int J Mol Sci. 22:27322021. View Article : Google Scholar : PubMed/NCBI

Maniero C, Scudieri P, Haris Shaikh L, Zhao W, Gurnell M, Galietta LJV and Brown MJ: ANO4 (Anoctamin 4) Is a novel marker of zona glomerulosa that regulates stimulated aldosterone secretion. Hypertension. 74:1152–1159. 2019. View Article : Google Scholar : PubMed/NCBI

Sherva R, Tripodis Y, Bennett DA, Chibnik LB, Crane PK, de Jager PL, Farrer LA, Saykin AJ, Shulman JM, Naj A, et al: Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimers Dement. 10:45–52. 2014. View Article : Google Scholar

Di Zanni E, Gradogna A, Scholz-Starke J and Boccaccio A: Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia. Cell Mol Life Sci. 75:1657–1670. 2017. View Article : Google Scholar : PubMed/NCBI

Di Zanni E, Gradogna A, Picco C, Scholz-Starke J and Boccaccio A: TMEM16E/ANO5 mutations related to bone dysplasia or muscular dystrophy cause opposite effects on lipid scrambling. Hum Mutat. 41:1157–1170. 2020. View Article : Google Scholar : PubMed/NCBI

Whitlock JM, Yu K, Cui YY and Hartzell HC: Anoctamin 5/TMEM16E facilitates muscle precursor cell fusion. J Gen Physiol. 150:1498–1509. 2018. View Article : Google Scholar : PubMed/NCBI

Foltz SJ, Cui YY, Choo HJ and Hartzell HC: ANO5 ensures trafficking of annexins in wounded myofibers. J Cell Biol. 220:e2020070592021. View Article : Google Scholar : PubMed/NCBI

van Kruchten R, Mattheij NJ, Saunders C, Feijge MA, Swieringa F, Wolfs JL, Collins PW, Heemskerk JW and Bevers EM: Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood. 121:1850–1857. 2013. View Article : Google Scholar : PubMed/NCBI

Arndt M, Alvadia C, Straub MS, Clerico Mosina V, Paulino C and Dutzler R: Structural basis for the activation of the lipid scramblase TMEM16F. Nat Commun. 13:66922022. View Article : Google Scholar : PubMed/NCBI

Fujii T, Sakata A, Nishimura S, Eto K and Nagata S: TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets. Proc Natl Acad Sci USA. 112:12800–12805. 2015. View Article : Google Scholar : PubMed/NCBI

Millington-Burgess SL and Harper MT: Gene of the issue: ANO6 and Scott syndrome. Platelets. 31:964–967. 2019. View Article : Google Scholar : PubMed/NCBI

Li H, Xu L, Gao Y, Zuo Y, Yang Z, Zhao L, Chen Z, Guo S and Han R: BVES is a novel interactor of ANO5 and regulates myoblast differentiation. Cell Biosci. 11:2222021. View Article : Google Scholar : PubMed/NCBI

Guo J, Wang D, Dong Y, Gao X, Tong H, Liu W, Zhang L and Sun M: ANO7: Insights into topology, function, and potential applications as a biomarker and immunotherapy target. Tissue Cell. 72:1015462021. View Article : Google Scholar : PubMed/NCBI

Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, et al: ANO7 is associated with aggressive prostate cancer. Int J Cancer. 143:2479–2487. 2018. View Article : Google Scholar : PubMed/NCBI

Jha A, Chung WY, Vachel L, Maleth J, Lake S, Zhang G, Ahuja M and Muallem S: Anoctamin 8 tethers endoplasmic reticulum and plasma membrane for assembly of Ca²⁺ signaling complexes at the ER/PM compartment. EMBO J. 38:e1014522019. View Article : Google Scholar

Liu X, Lai H, Zeng X, Xin S, Nie L, Liang Z, Wu M, Chen Y, Zheng J and Zou Y: Whole-exome sequencing reveals ANO8 as a genetic risk factor for intrahepatic cholestasis of pregnancy. BMC Pregnancy Childbirth. 20:5442020. View Article : Google Scholar : PubMed/NCBI

Schreiber R, Ousingsawat J and Kunzelmann K: Targeting of intracellular TMEM16 proteins to the plasma membrane and activation by purinergic signaling. Int J Mol Sci. 21:40652020. View Article : Google Scholar : PubMed/NCBI

Katsurahara K, Shiozaki A, Kosuga T, Kudou M, Shoda K, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, et al: ANO9 regulated cell cycle in human esophageal squamous cell carcinoma. Ann Surg Oncol. 27:3218–3230. 2020. View Article : Google Scholar : PubMed/NCBI

Katsurahara K, Shiozaki A, Kosuga T, Shimizu H, Kudou M, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, et al: ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer. Cancer Sci. 112:1026–1037. 2021. View Article : Google Scholar : PubMed/NCBI

Jun I, Park HS, Piao H, Han JW, An MJ, Yun BG, Zhang X, Cha YH, Shin YK, Yook JI, et al: ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. Br J Cancer. 117:1798–1809. 2017. View Article : Google Scholar : PubMed/NCBI

Schreiber R, Talbi K, Ousingsawat J and Kunzelmann K: A TMEM16J variant leads to dysregulated cytosolic calcium which may lead to renal disease. FASEB J. 37:e226832023. View Article : Google Scholar

Chrysanthou A, Ververis A and Christodoulou K: ANO10 function in health and disease. Cerebellum. 22:447–467. 2022. View Article : Google Scholar : PubMed/NCBI

Wanitchakool P, Ousingsawat J, Sirianant L, Cabrita I, Faria D, Schreiber R and Kunzelmann K: Cellular defects by deletion of ANO10 are due to deregulated local calcium signaling. Cell Signal. 30:41–49. 2017. View Article : Google Scholar

Hammer C, Wanitchakool P, Sirianant L, Papiol S, Monnheimer M, Faria D, Ousingsawat J, Schramek N, Schmitt C, Margos G, et al: A coding variant of ANO10, affecting volume regulation of macrophages, is associated with borrelia seropositivity. Mol Med. 21:26–37. 2015. View Article : Google Scholar : PubMed/NCBI

Gentzsch M and Mall MA: Ion channel modulators in cystic fibrosis. Chest. 154:383–393. 2018. View Article : Google Scholar : PubMed/NCBI

Shteinberg M, Haq IJ, Polineni D and Davies JC: Cystic fibrosis. Lancet. 397:2195–2211. 2021. View Article : Google Scholar : PubMed/NCBI

Lopes-Pacheco M, Pedemonte N and Veit G: Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov. 16:897–913. 2021. View Article : Google Scholar : PubMed/NCBI

Villamizar O, Waters SA, Scott T, Grepo N, Jaffe A and Morris KV: Mesenchymal Stem Cell exosome delivered Zinc Finger Protein activation of cystic fibrosis transmembrane conductance regulator. J Extracell Vesicles. 10:e120532021. View Article : Google Scholar : PubMed/NCBI

Simon MA and Csanady L: Understanding impact of δF508 and G551D CFTR mutations on CFTR/PKA-c interaction. Biophys J. 122:112a2023. View Article : Google Scholar

Harrison MJ, Murphy DM and Plant BJ: Ivacaftor in a G551D homozygote with cystic fibrosis. N Engl J Med. 369:1280–1282. 2013. View Article : Google Scholar : PubMed/NCBI

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al: A CFTR potentiator in patients with cystic fibrosis and theG551Dmutation. N Engl J Med. 365:1663–1672. 2011. View Article : Google Scholar : PubMed/NCBI

Fiedorczuk K and Chen J: Mechanism of CFTR correction by type I folding correctors. Cell. 185:158–168.e11. 2022. View Article : Google Scholar : PubMed/NCBI

Veit G, Roldan A, Hancock MA, Da Fonte DF, Xu H, Hussein M, Frenkiel S, Matouk E, Velkov T and Lukacs GL: Allosteric folding correction of F508del and rare CFTR mutants by Elexacaftor-Tezacaftor-Ivacaftor (Trikafta) combination. JCI Insight. 5:e1399832020. View Article : Google Scholar : PubMed/NCBI

Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D and Boyle MP; VX09-809-102 Study Group: Lumacaftor/Ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. Ann Am Thorac Soc. 14:213–219. 2017. View Article : Google Scholar :

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, et al: Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508delCFTR. N Engl J Med. 373:220–231. 2015. View Article : Google Scholar : PubMed/NCBI

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al: Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation. Thorax. 67:12–18. 2011. View Article : Google Scholar

Flume PA, Harris RS, Paz-Diaz H, Ahluwalia N, Higgins M, Campbell D, Berhane I, Shih JL and Sawicki G: Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial. J Cyst Fibros. 22:464–470. 2023. View Article : Google Scholar

Bruscia EM: The effects of Elexacaftor/Tezacaftor/Ivacaftor beyond the epithelium: Spurring macrophages to fight infections. Eur Respir J. 61:23002162023. View Article : Google Scholar

Sawicki GS, Van Brunt K, Booth J, Bailey E, Millar SJ, Konstan MW and Flume PA: Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 21:96–103. 2022. View Article : Google Scholar :

Galietta LJV: TMEM16A (ANO1) as a therapeutic target in cystic fibrosis. Curr Opin Pharmacol. 64:1022062022. View Article : Google Scholar : PubMed/NCBI

Simões FB, Quaresma MC, Clarke LA, Silva IA, Pankonien I, Railean V, Kmit A and Amaral MD: TMEM16A chloride channel does not drive mucus production. Life Sci Alliance. 2:e2019004622019. View Article : Google Scholar : PubMed/NCBI

Ruffin M, Voland M, Marie S, Bonora M, Blanchard E, Blouquit-Laye S, Naline E, Puyo P, Le Rouzic P, Guillot L, et al: Anoctamin 1 dysregulation alters bronchial epithelial repair in cystic fibrosis. Biochim Biophys Acta. 1832:2340–2351. 2013. View Article : Google Scholar : PubMed/NCBI

Kirk KL and Wang W: A unified view of cystic fibrosis transmembrane conductance regulator (CFTR) gating: Combining the allosterism of a ligand-gated channel with the enzymatic activity of an ATP-binding cassette (ABC) transporter. J Biol Chem. 286:12813–12819. 2011. View Article : Google Scholar : PubMed/NCBI

Deng Z, Chen X, Lin Z, Alahdal M, Wang D, Liu J and Li W: The homeostasis of cartilage matrix remodeling and the regulation of volume-sensitive ion channel. Aging Dis. 13:787–800. 2022. View Article : Google Scholar : PubMed/NCBI

Talbi K, Ousingsawat J, Centeio R, Schreiber R and Kunzelmann K: Calmodulin-dependent regulation of overexpressed but not endogenous TMEM16A expressed in airway epithelial cells. Membranes (Basel). 11:7232021. View Article : Google Scholar : PubMed/NCBI

Cabrita I, Benedetto R, Schreiber R and Kunzelmann K: Niclosamide repurposed for the treatment of inflammatory airway disease. JCI Insight. 4:e1284142019. View Article : Google Scholar : PubMed/NCBI

Danahay H, Fox R, Lilley S, Charlton H, Adley K, Christie L, Ansari E, Ehre C, Flen A, Tuvim MJ, et al: Potentiating TMEM16A does not stimulate airway mucus secretion or bronchial and pulmonary arterial smooth muscle contraction. FASEB Bioadv. 2:464–477. 2020. View Article : Google Scholar : PubMed/NCBI

Danahay HL, Lilley S, Fox R, Charlton H, Sabater J, Button B, McCarthy C, Collingwood SP and Gosling M: TMEM16A potentiation: A novel therapeutic approach for the treatment of cystic fibrosis. Am J Respir Crit Care Med. 201:946–954. 2020. View Article : Google Scholar : PubMed/NCBI

Ousingsawat J, Centeio R, Cabrita I, Talbi K, Zimmer O, Graf M, Göpferich A, Schreiber R and Kunzelmann K: Airway delivery of hydrogel-encapsulated niclosamide for the treatment of inflammatory airway disease. Int J Mol Sci. 23:10852022. View Article : Google Scholar : PubMed/NCBI

Centeio R, Ousingsawat J, Cabrita I, Schreiber R, Talbi K, Benedetto R, Doušová T, Verbeken EK, De Boeck K, Cohen I and Kunzelmann K: Mucus release and airway constriction by TMEM16A may worsen pathology in inflammatory lung disease. Int J Mol Sci. 22:78522021. View Article : Google Scholar : PubMed/NCBI

Sonneville F, Ruffin M, Coraux C, Rousselet N, Le Rouzic P, Blouquit-Laye S, Corvol H and Tabary O: MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology. Nat Commun. 8:7102017. View Article : Google Scholar : PubMed/NCBI

Kamaleddin MA: Molecular, biophysical, and pharmacological properties of calcium-activated chloride channels. J Cell Physiol. 233:787–798. 2017. View Article : Google Scholar : PubMed/NCBI

Sah SP and McCluggage WG: DOG1 immunoreactivity in uterine leiomyosarcomas. J Clin Pathol. 66:40–43. 2012. View Article : Google Scholar : PubMed/NCBI

Filippou A, Pehkonen H, Karhemo PR, Väänänen J, Nieminen AI, Klefström J, Grénman R, Mäkitie AA, Joensuu H and Monni O: ANO1 expression orchestrates p27Kip1/MCL1-Mediated signaling in head and neck squamous cell carcinoma. Cancers (Basel). 13:11702021. View Article : Google Scholar : PubMed/NCBI

Ishaque N, Abba ML, Hauser C, Patil N, Paramasivam N, Huebschmann D, Leupold JH, Balasubramanian GP, Kleinheinz K, Toprak UH, et al: Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nat Commun. 9:47822018. View Article : Google Scholar : PubMed/NCBI

Sauter DRP, Novak I, Pedersen SF, Larsen EH and Hoffmann EK: ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC). Pflugers Arch. 467:1495–1508. 2015. View Article : Google Scholar :

Song Y, Gao J, Guan L, Chen X, Gao J and Wang K: Inhibition of ANO1/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-α signaling. Cell Death Dis. 9:7032018. View Article : Google Scholar

Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, Rebhan M, Raman P, Guy CT, Wetzel K, et al: Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci USA. 110:E1026–E1034. 2013. View Article : Google Scholar : PubMed/NCBI

Sui Y, Sun M, Wu F, Yang L, Di W, Zhang G, Zhong L, Ma Z, Zheng J, Fang X and Ma T: Inhibition of TMEM16A expression suppresses growth and invasion in human colorectal cancer cells. PLoS One. 9:e1154432014. View Article : Google Scholar : PubMed/NCBI

Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017. View Article : Google Scholar : PubMed/NCBI

Lee YS, Lee JK, Bae Y, Lee BS, Kim E, Cho CH, Ryoo K, Yoo J, Kim CH, Yi GS, et al: Suppression of 14-3-3γ-mediated surface expression of ANO1 inhibits cancer progression of glioblastoma cells. Sci Rep. 6:264132016. View Article : Google Scholar

Shang L, Hao JJ, Zhao XK, He JZ, Shi ZZ, Liu HJ, Wu LF, Jiang YY, Shi F, Yang H, et al: ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction. Oncotarget. 7:24374–24382. 2016. View Article : Google Scholar : PubMed/NCBI

Akpalo H, Lange C and Zustin J: Discovered on gastrointestinal stromal tumour 1 (DOG1): A useful immunohistochemical marker for diagnosing chondroblastoma. Histopathology. 60:1099–1106. 2012. View Article : Google Scholar : PubMed/NCBI

Chang Z, Cai C, Han D, Gao Y, Li Q, Feng L, Zhang W, Zheng J, Jin J, Zhang H and Wei Q: Anoctamin5 regulates cell migration and invasion in thyroid cancer. Int J Oncol. 51:1311–1319. 2017. View Article : Google Scholar : PubMed/NCBI

Li Y, Wang X, Vural S, Mishra NK, Cowan KH and Guda C: Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers. PLoS One. 10:e01193832015. View Article : Google Scholar : PubMed/NCBI

Chen W, Gu M, Gao C, Chen B, Yang J, Xie X, Wang X, Sun J and Wang J: The prognostic value and mechanisms of TMEM16A in human cancer. Front Mol Biosci. 8:5421562021. View Article : Google Scholar : PubMed/NCBI

Liu F, Yang X, Geng M and Huang M: Targeting ERK, an Achilles' heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 8:552–562. 2018. View Article : Google Scholar : PubMed/NCBI

Wang H, Yao F, Luo S, Ma K, Liu M, Bai L, Chen S, Song C, Wang T, Du Q, et al: A mutual activation loop between the Ca²⁺-activated chloride channel TMEM16A and EGFR/STAT3 signaling promotes breast cancer tumorigenesis. Cancer Lett. 455:48–59. 2019. View Article : Google Scholar : PubMed/NCBI

Bai W, Liu M and Xiao Q: The diverse roles of TMEM16A Ca²⁺-activated Cl-channels in inflammation. J Adv Res. 33:53–68. 2021. View Article : Google Scholar : PubMed/NCBI

Lin Z, Deng Z, Liu J, Lin Z, Chen S, Deng Z and Li W: Chloride channel and inflammation-mediated pathogenesis of osteoarthritis. J Inflamm Res. 15:953–964. 2022. View Article : Google Scholar : PubMed/NCBI

Liu J, Liu Y, Ren Y, Kang L and Zhang L: Transmembrane protein with unknown function 16A overexpression promotes glioma formation through the nuclear factor-κB signaling pathway. Mol Med Report. 9:1068–1074. 2014. View Article : Google Scholar

Zhou L, Deng ZZ, Li HY, Jiang N, Wei ZS, Hong MF, Chen XD, Wang JH, Zhang MX, Shi YH, et al: TRIM31 promotes glioma proliferation and invasion through activating NF-κB pathway. Onco Targets Ther. 12:2289–2297. 2019. View Article : Google Scholar :

Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, et al: TMEM 16 A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res. 72:3270–3281. 2012. View Article : Google Scholar : PubMed/NCBI

Deng L, Yang J, Chen H, Ma B, Pan K, Su C, Xu F and Zhang J: Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma. Onco Targets Ther. 9:325–333. 2016.PubMed/NCBI

Ruiz C, Martins JR, Rudin F, Schneider S, Dietsche T, Fischer CA, Tornillo L, Terracciano LM, Schreiber R, Bubendorf L and Kunzelmann K: Enhanced expression of ANO1 in head and neck squamous cell carcinoma causes cell migration and correlates with poor prognosis. PLoS One. 7:e432652012. View Article : Google Scholar : PubMed/NCBI

Dixit R, Kemp C, Kulich S, Seethala R, Chiosea S, Ling S, Ha PK and Duvvuri U: TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation. Sci Rep. 5:166572015. View Article : Google Scholar : PubMed/NCBI

Mokutani Y, Uemura M, Munakata K, Okuzaki D, Haraguchi N, Takahashi H, Nishimura J, Hata T, Murata K, Takemasa I, et al: Down-regulation of microRNA-132 is associated with poor prognosis of colorectal cancer. Ann Surg Oncol. 23:599–608. 2016. View Article : Google Scholar : PubMed/NCBI

Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI

Wang H, Zou L, Ma K, Yu J, Wu H, Wei M and Xiao Q: Cell-specific mechanisms of TMEM16A Ca²⁺-activated chloride channel in cancer. Mol Cancer. 16:1522017. View Article : Google Scholar

Wanitchakool P, Wolf L, Koehl GE, Sirianant L, Schreiber R, Kulkarni S, Duvvuri U and Kunzelmann K: Role of anoctamins in cancer and apoptosis. Philos Trans R Soc Lond B Biol Sci. 369:201300962014. View Article : Google Scholar : PubMed/NCBI

Ahn SY, Yang JH, Kim NH, Lee K, Cha YH, Yun JS, Kang HE, Lee Y, Choi J, Kim HS and Yook J: Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3. Oncotarget. 8:31856–31863. 2017. View Article : Google Scholar : PubMed/NCBI

Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K, Elliott R, Chen JJ, Liu L, Leith A, et al: Drug repurposing: The anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front Pharmacol. 10:512019. View Article : Google Scholar : PubMed/NCBI

Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J and Pan J: Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: Inactivation of the NF-κB pathway and generation of reactive oxygen species. Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI

Han Z, Li Q, Wang Y, Wang L, Li X, Ge N, Wang Y and Guo C: Niclosamide induces cell cycle arrest in G1 phase in head and neck squamous cell carcinoma through Let-7d/CDC34 Axis. Front Pharmacol. 9:15442019. View Article : Google Scholar : PubMed/NCBI

Li Y, Li PK, Roberts MJ, Arend RC, Samant RS and Buchsbaum DJ: Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett. 349:8–14. 2014. View Article : Google Scholar : PubMed/NCBI

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, et al: Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 9:19459. 2018. View Article : Google Scholar

Lafkas D, Shelton A, Chiu C, de Leon Boenig G, Chen Y, Stawicki SS, Siltanen C, Reichelt M, Zhou M, Wu X, et al: Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature. 528:127–131. 2015. View Article : Google Scholar : PubMed/NCBI

Danahay H, Pessotti AD, Coote J, Montgomery BE, Xia D, Wilson A, Yang H, Wang Z, Bevan L, Thomas C, et al: Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung. Cell Rep. 10:239–252. 2015. View Article : Google Scholar : PubMed/NCBI

Seo Y, Kim J, Chang J, Kim SS, Namkung W and Kim I: Synthesis and biological evaluation of novel Ani9 derivatives as potent and selective ANO1 inhibitors. Eur J Medicinal Chem. 160:245–255. 2018. View Article : Google Scholar

Burock S, Daum S, Keilholz U, Neumann K, Walther W and Stein U: Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: The NIKOLO trial. BMC Cancer. 18:2972018. View Article : Google Scholar : PubMed/NCBI

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, et al: Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One. 13:e02027092018. View Article : Google Scholar : PubMed/NCBI

Yan Y, Ding X, Han C, Gao J, Liu Z, Liu Y and Wang K: Involvement of TMEM16A/ANO1 upregulation in the oncogenesis of colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 1868:1663702022. View Article : Google Scholar : PubMed/NCBI

Khalil A, Elesawy BH, Ali TM and Ahmed OM: Bee venom: From venom to drug. Molecules. 26:49412021. View Article : Google Scholar : PubMed/NCBI

Badawi JK: Bee venom components as therapeutic tools against prostate cancer. Toxins (Basel). 13:3372021. View Article : Google Scholar : PubMed/NCBI

Schreiber R, Ousingsawat J, Wanitchakool P, Sirianant L, Benedetto R, Reiss K and Kunzelmann K: Regulation of TMEM16A/ANO1 and TMEM16F/ANO6 ion currents and phospholipid scrambling by Ca²⁺ and plasma membrane lipid. J Physiol. 596:217–229. 2017. View Article : Google Scholar

Simões F, Ousingsawat J, Wanitchakool P, Fonseca A, Cabrita I, Benedetto R, Schreiber R and Kunzelmann K: CFTR supports cell death through ROS-dependent activation of TMEM16F (anoctamin 6). Pflugers Arch. 470:305–314. 2017. View Article : Google Scholar : PubMed/NCBI

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, et al: Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 171:273–285. 2017. View Article : Google Scholar : PubMed/NCBI

Xue Q, Yan D, Chen X, Li X, Kang R, Klionsky DJ, Kroemer G, Chen X, Tang D and Liu J: Copper-dependent autophagic degradation of GPX4 drives ferroptosis. Autophagy. 19:1982–1996. 2023. View Article : Google Scholar : PubMed/NCBI

El-Didamony SE, Amer RI and El-Osaily GH: Formulation, characterization and cellular toxicity assessment of a novel bee-venom microsphere in prostate cancer treatment. Sci Rep. 12:132132022. View Article : Google Scholar : PubMed/NCBI

Schreiber R, Buchholz B, Kraus A, Schley G, Scholz J, Ousingsawat J and Kunzelmann K: Lipid peroxidation drives renal cyst growth in vitro through activation of TMEM16A. J Am Soc Nephrol. 30:228–242. 2019. View Article : Google Scholar : PubMed/NCBI

Schmaier AA, Anderson PF, Chen SM, El-Darzi E, Aivasovsky I, Kaushik MP, Sack KD, Hartzell HC, Parikh SM, Flaumenhaft R and Schulman S: TMEM16E regulates endothelial cell procoagulant activity and thrombosis. J Clin Invest. 133:e1638082023. View Article : Google Scholar : PubMed/NCBI

Fujii Y, Taniguchi M, Nagaya S, Ueda Y, Hashizume C, Watanabe K, Takeya H, Kosaka T and Okazaki T: A novel mechanism of thrombocytopenia by PS exposure through TMEM16F in sphingomyelin synthase 1 deficiency. Blood Adv. 5:4265–4277. 2021. View Article : Google Scholar : PubMed/NCBI

Filep JG: Two to tango: Endothelial cell TMEM16 scramblases drive coagulation and thrombosis. J Clin Invest. 133:e1706432023. View Article : Google Scholar : PubMed/NCBI

Wu N, Cernysiov V, Davidson D, Song H, Tang J, Luo S, Lu Y, Qian J, Gyurova IE, Waggoner SN, et al: Critical role of lipid scramblase TMEM16F in phosphatidylserine exposure and repair of plasma membrane after pore formation. Cell Rep. 30:1129–1140.e5. 2020. View Article : Google Scholar : PubMed/NCBI

Taylor KA and Mahaut-Smith MP: A major interspecies difference in the ionic selectivity of megakaryocyte Ca²⁺-activated channels sensitive to the TMEM16F inhibitor CaCCinh-A01. Platelets. 30:962–966. 2019. View Article : Google Scholar :

Yang H, Kim A, David T, Palmer D, Jin T, Tien J, Huang F, Cheng T, Coughlin SR, Jan YN and Jan LY: TMEM16F Forms a Ca²⁺-activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell. 151:111–122. 2012. View Article : Google Scholar : PubMed/NCBI

Yu H, Wang Z, Li Z, An Y, Yan M, Ji S, Xu M, Wang L, Dong W, Shi J and Gao C: Hyperuricemia enhances procoagulant activity of vascular endothelial cells through TMEM16F regulated phosphatidylserine exposure and microparticle release. FASEB J. 35:e218082021. View Article : Google Scholar : PubMed/NCBI

Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR Jr, Nahid M, Ringel JB, et al: Clinical characteristics of Covid-19 in new york city. N Engl J Med. 382:2372–2374. 2020. View Article : Google Scholar : PubMed/NCBI

Levi M, Thachil J, Iba T and Levy JH: Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 7:e438–e440. 2020. View Article : Google Scholar : PubMed/NCBI

Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, Klein A, Langenwalder F, Lütgehetmann M, Meißner K, et al: Correction to: Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med. 134:19772020. View Article : Google Scholar : PubMed/NCBI

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI

Hoffmann M, Hofmann-Winkler H and Pöhlmann S: Priming time: How Cellular Proteases Arm Coronavirus Spike Proteins. Springer International Publishing; Cham: pp. 71–98. 2018

Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D, Penn R, Jimenez-Guardeño JM, Ortega-Prieto AM, Bussani R, et al: Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature. 594:88–93. 2021. View Article : Google Scholar : PubMed/NCBI

Cappelletto A, Allan HE, Crescente M, Schneider E, Bussani R, Ali H, Secco I, Vodret S, Simeone R, Mascaretti L, et al: SARS-CoV-2 Spike protein activates TMEM16F-mediated platelet procoagulant activity. Front Cardiovasc Med. 9:10132622023. View Article : Google Scholar : PubMed/NCBI

Abdulamir AS, Gorial FI, Saadi SJ, Maulood MF, Hashim HA, Alnuaimi AS and Abdulrrazaq MK: A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management. Ann Med Surg (Lond). 69:1027792021.PubMed/NCBI

Chen W, Mook RA Jr, Premont RT and Wang J: Niclosamide: Beyond an antihelminthic drug. Cell Signal. 41:89–96. 2018. View Article : Google Scholar

Kalienkova V, Clerico Mosina V and Paulino C: The Groovy TMEM16 family: Molecular mechanisms of lipid scrambling and ion conduction. J Mol Biol. 433:1669412021. View Article : Google Scholar : PubMed/NCBI

Lam AKM, Rutz S and Dutzler R: Inhibition mechanism of the chloride channel TMEM16A by the pore blocker 1PBC. Nat Commun. 13:27982022. View Article : Google Scholar : PubMed/NCBI

Bill A, Gutierrez A, Kulkarni S, Kemp C, Bonenfant D, Voshol H, Duvvuri U and Gaither LA: ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget. 6:9173–9188. 2015. View Article : Google Scholar : PubMed/NCBI

Zhang X, Zhang G, Zhai W, Zhao Z, Wang S and Yi J: Inhibition of TMEM16A Ca²⁺-activated Cl-channels by avermectins is essential for their anticancer effects. Pharmacol Res. 156:1047632020. View Article : Google Scholar

Fang H, Deng Z, Liu J, Chen S, Deng Z and Li W: The mechanism of bone remodeling after bone aging. Clin Interv Aging. 17:405–415. 2022. View Article : Google Scholar : PubMed/NCBI

Genovese M, Buccirossi M, Guidone D, De Cegli R, Sarnataro S, di Bernardo D and Galietta LJV: Analysis of inhibitors of the anoctamin-1 chloride channel (transmembrane member 16A, TMEM16A) reveals indirect mechanisms involving alterations in calcium signalling. Br J Pharmacol. 180:775–785. 2023. View Article : Google Scholar

Shaibani A, Khan S and Shinawi M: Autosomal dominant ANO5-Related disorder associated with myopathy and gnathodiaphyseal dysplasia. Neurol Genet. 7:e6122021. View Article : Google Scholar : PubMed/NCBI

Liu X, Wang X, Ma X, Li H, Miao C, Tian Z and Hu Y: Genetic disruption of Ano5 leads to impaired osteoclastogenesis for gnathodiaphyseal dysplasia. Oral Dis. 30:1403–1415. 2024. View Article : Google Scholar

Chandra G, Defour A, Mamchoui K, Pandey K, Mishra S, Mouly V, Sreetama S, Mahad Ahmad M, Mahjneh I, Morizono H, et al: Dysregulated calcium homeostasis prevents plasma membrane repair in Anoctamin 5/TMEM16E-deficient patient muscle cells. Cell Death Discov. 5:1182019. View Article : Google Scholar : PubMed/NCBI

Thiruvengadam G, Sreetama SC, Charton K, Hogarth M, Novak JS, Suel-Petat L, Chandra G, Allard B, Richard I and Jaiswal JK: Anoctamin 5 Knockout mouse model recapitulates LGMD2L muscle pathology and offers insight into in vivo functional deficits. J Neuromuscul Dis. 8(Suppl): S243–S255. 2021. View Article : Google Scholar : PubMed/NCBI

Li H, Wang X, Chen E, Liu X, Ma X, Miao C, Tian Z, Dong R and Hu Y: Introduction of a Cys360Tyr Mutation in ANO5 creates a mouse model for gnathodiaphyseal dysplasia. J Bone Miner Res. 37:515–530. 2022. View Article : Google Scholar

Jiang LT, Li LX, Liu Y, Zhang XL, Pan YG, Wang L, Wan XH and Jin LJ: The expanding clinical and genetic spectrum of ANO3 dystonia. Neurosci Lett. 746:1355902021. View Article : Google Scholar : PubMed/NCBI